|
Dr. Klaus Nickisch is a senior executive with broad experience in scientific, technical, business, and managerial matters related to the chemical/pharmaceutical industry. Dr. Nickisch has in depth knowledge in the fields of oncology, CNS, and female health and experience in all aspects of the drug development process in the US and Europe. Dr. Nickisch has extensive experience in project management; portfolio and alliance management; contract negotiations; technology assessment; process development; and the production of both small molecules and bio-therapeutics. Dr. Nickisch has been a long time employee of Shering AG / Berlex Pharmaceuticals, Inc. During his tenure at Schering / Berlex (1979-2006) Dr. Nickisch held a number of titles including Senior Vice President for Global Project Management; Vice President, Corporate Portfolio and Project Management; Vice President of Portfolio and Cooperation Management Oncology; Project Leader for Female Health and Therapeutics; Vice President of Chemical Development; and Director, Process Research. Dr. Nickisch has been a faculty member of the Institute for Organic Chemisty Hannover since 1993, and a lecturer at University of Witten-Herdecke in Project Management since 2002. He serves on three Advisory Boards: Metallchemie Germany, Heyl Pharmaceuticals, and Laborchemie Apolda. He joined the Board of Directors of EpiVax in 2006. Dr. Nickisch earned both his M.S. in Chemistry (Summa Cum Laude) and Ph.D. in Organic Chemistry (Summa Cum Laude) from the Technical University of Berlin. | 